MedTrace Logo

Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

NCT04631445 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-02-21

No results posted yet for this study

Summary

This study will evaluate the effects of the ketogenic diet in patients with metastatic pancreatic cancer while receiving chemotherapy.

Conditions

Interventions

OTHER

Ketogenic Diet

Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).

Sponsors & Collaborators

  • Translational Genomics Research Institute

    collaborator OTHER

  • Translational Drug Development

    lead OTHER

Principal Investigators

  • Steve Norton, MBA PhD · Translational Drug Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2025-02-01
Completion
2025-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04631445 on ClinicalTrials.gov